Ray Therapeutics Raises $125M to Fund Pivotal Optogenetic Therapy Trial in Retinitis Pigmentosa
Ray Therapeutics, a biopharma startup, has raised $125 million in Series B funding to advance its optogenetic gene therapy for retinitis pigmentosa. The company plans to use the funds to support late-stage clinical development and commercial readiness for its lead program, RTx-015.
Ray Therapeutics, a Berkeley, California-based biopharma startup, has secured $125 million in Series B funding. The funding round was led by Janus Henderson Investors and included existing investors like Deerfield Management and Novo Holdings. The company will use the funds to advance its pipeline of optogenetic gene therapies, particularly its lead program, RTx-015, for retinitis pigmentosa. RTx-015 is being evaluated in the Phase I ENVISION trial and is expected to enter a registrational Phase II/III trial later this year. The therapy involves delivering engineered channelrhodopsins to retinal ganglion cells to restore visual function. Ray Therapeutics was founded in 2021 and has previously raised $100 million in Series A funding and $6 million in seed funds.
This content was automatically generated and/or translated by AI. It may contain inaccuracies. Please refer to the original sources for verification.